Study title: Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.Speders S, Sosna J, Schumacher A, Pfennigsdorf G. Journal of cardiovascular pharmacology, 1989, vol. 13 Suppl 4, p. S47−9,Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.Speders S, Sosna J, Schumacher A, Pfennigsdorf G. Journal of cardiovascular pharmacology, 1989, vol. 13 Suppl 4, p. S47−9,
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Cardiovascular Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: VERAPAMIL | |||||
| ATC code: C08D A01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |